Several brokerages have updated their recommendations and price targets on shares of Nabriva Therapeutics AG (NASDAQ: NBRV) in the last few weeks:

  • 9/19/2017 – Nabriva Therapeutics AG had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
  • 9/19/2017 – Nabriva Therapeutics AG had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock, up previously from $15.00.
  • 9/18/2017 – Nabriva Therapeutics AG had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $22.00 price target on the stock, up previously from $20.00.
  • 9/18/2017 – Nabriva Therapeutics AG had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
  • 9/18/2017 – Nabriva Therapeutics AG had its price target raised by analysts at SunTrust Banks, Inc. from $20.00 to $24.00. They now have a “buy” rating on the stock.
  • 9/18/2017 – Nabriva Therapeutics AG had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $21.00 price target on the stock, up previously from $13.00.
  • 9/1/2017 – Nabriva Therapeutics AG had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock. They wrote, “Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017.””
  • 8/28/2017 – Nabriva Therapeutics AG had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock, up previously from $16.00.
  • 8/25/2017 – Nabriva Therapeutics AG is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $20.00 price target on the stock.
  • 8/15/2017 – Nabriva Therapeutics AG was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
  • 8/10/2017 – Nabriva Therapeutics AG was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.71% during mid-day trading on Thursday, reaching $8.41. 481,516 shares of the company were exchanged. The stock’s market capitalization is $225.71 million. The stock has a 50 day moving average of $8.52 and a 200-day moving average of $9.92. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. On average, equities analysts expect that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current fiscal year.

In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the business’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $10.51, for a total transaction of $734,165.54. Following the transaction, the insider now owns 2,490,952 shares in the company, valued at $26,179,905.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the business’s stock in a transaction on Monday, September 18th. The shares were purchased at an average price of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 57,219 shares of company stock worth $535,919 and have sold 255,540 shares worth $2,614,045. Company insiders own 2.75% of the company’s stock.

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.